Imaging of abdominal aortic aneurysm: The present and the future

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 808-819

  Hong, Hao ^a   Yang, Yunan ^a   Liu, Bo ^a   Cai, Weibo ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Abdominal aortic aneurysm (AAA); Anatomical imaging; Functional imaging; Magnetic resonance imaging (MRI); Molecular imaging; Positron emission tomography (PET); Ultrasound

Indexed keywords

ANNEXIN V TC 99M; ERYTHROCYTE TC 99M; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE ELASTASE; MATRILYSIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCYTE CHEMOTACTIC PROTEIN 1; RADIOPHARMACEUTICAL AGENT; STROMELYSIN; THALLIUM 201; THROMBOCYTE IN 111; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOKINE PRODUCTION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DOPPLER IMAGING; ULTRASOUND;

EID: 78649365029     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563898     Document Type: Article

References (143)

1. Belsley SJ, Tilson MD. Two decades of research on etiology andgenetic factors in the abdominal aortic aneurysm (AAA)--with aglimpse into the 21st century. Acta Chir Belg 2003; 103: 187-96.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA CancerJ Clin 2008; 58: 71-96.
3. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graftimplantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5: 491-9.
4. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparingconventional and endovascular repair of abdominal aorticaneurysms. N Engl J Med 2004; 351: 1607-18.
5. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms.Arterioscler Thromb Vasc Biol 2004; 24: 429-34.
6. McMillan WD, Patterson BK, Keen RR, Pearce WH. In situ localizationand quantification of seventy-two-kilodalton type IV collagenasein aneurysmal, occlusive, and normal aorta. J Vasc Surg 1995; 22: 295-305.
7. Higashikata T, Yamagishi M, Sasaki H, et al. Application of realtimeRT-PCR to quantifying gene expression of matrix metalloproteinasesand tissue inhibitors of metalloproteinases in human abdominalaortic aneurysm. Atherosclerosis 2004; 177: 353-60.
8. Carrell TW, Burnand KG, Wells GM, Clements JM, Smith A.Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor ofmetalloproteinase-3 are overexpressed in the wall of abdominalaortic aneurysms. Circulation 2002; 105: 477-82.
9. Fontaine V, Jacob MP, Houard X, et al. Involvement of the muralthrombus as a site of protease release and activation in human aorticaneurysms. Am J Pathol 2002; 161: 1701-10.
10. McMillan WD, Patterson BK, Keen RR, et al. In situ localizationand quantification of mRNA for 92-kD type IV collagenase and itsinhibitor in aneurysmal, occlusive, and normal aorta. ArteriosclerThromb Vasc Biol 1995; 15: 1139-44.
11. Hovsepian DM, Ziporin SJ, Sakurai MK, et al. Elevated plasmalevels of matrix metalloproteinase-9 in patients with abdominalaortic aneurysms: a circulating marker of degenerative aneurysmdisease. J Vasc Interv Radiol 2000; 11: 1345-52.
12. Elmore JR, Keister BF, Franklin DP, Youkey JR, Carey DJ. Expressionof matrix metalloproteinases and TIMPs in human abdominalaortic aneurysms. Ann Vasc Surg 1998; 12: 221-8.
13. Annabi B, Shedid D, Ghosn P, et al. Differential regulation ofmatrix metalloproteinase activities in abdominal aortic aneurysms.J Vasc Surg 2002; 35: 539-46.
14. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW.Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998; 102: 1900-10.
15. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption ofmatrix metalloproteinase-9 (gelatinase B) suppresses developmentof experimental abdominal aortic aneurysms. J Clin Invest 2000;105: 1641-9.
16. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-32.
17. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline todecrease the growth rate of abdominal aortic aneurysms: a randomized,double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606-10.
18. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administrationof doxycycline in patients with small asymptomatic abdominal aorticaneurysms: report of a prospective (Phase II) multicenter study.J Vasc Surg 2002; 36: 1-12.
19. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Are statinsan option in the management of abdominal aortic aneurysms? VascEndovasc Surg 2008; 42: 128-34.
20. Stalenhoef AF. The benefit of statins in non-cardiac vascular surgerypatients. J Vasc Surg 2009; 49: 260-5.
21. Ailawadi G, Eliason JL, Upchurch GR, Jr. Current concepts in thepathogenesis of abdominal aortic aneurysm. J Vasc Surg 2003; 38:584-8.
22. Eliason JL, Hannawa KK, Ailawadi G, et al. Neutrophil depletioninhibits experimental abdominal aortic aneurysm formation. Circulation 2005; 112: 232-40.
23. Xiong W, Zhao Y, Prall A, Greiner TC, Baxter BT. Key roles ofCD4 T cells and IFN-gamma in the development of abdominalaortic aneurysms in a murine model. J Immunol 2004; 172: 2607-12.
24. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesisof elastase-induced abdominal aortic aneurysms in mice. JClin Invest 2007; 117: 3359-68.
25. Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signalinginduce aneurysms in allografted aortas. J Clin Invest 2004; 114:300-8.
26. Wassef M, Upchurch GR, Jr., Kuivaniemi H, Thompson RW, Tilson MD., 3rd. Challenges and opportunities in abdominal aorticaneurysm research. J Vasc Surg 2007; 45: 192-8.
27. Coll B, Alonso-Villaverde C, Joven J. Monocyte chemoattractantprotein-1 and atherosclerosis: is there room for an additional biomarker? Clin Chim Acta 2007; 383: 21-9.
28. Dawson J, Miltz W, Mir AK, Wiessner C. Targeting monocytechemoattractant protein-1 signalling in disease. Expert Opin TherTargets 2003; 7: 35-48.
29. Schubl S, Tsai S, Ryer EJ, et al. Upregulation of protein kinasecdelta in vascular smooth muscle cells promotes inflammation inabdominal aortic aneurysm. J Surg Res 2009; 153: 181-7.
30. Ishibashi M, Egashira K, Zhao Q, et al. Bone marrow-derivedmonocyte chemoattractant protein-1 receptor CCR2 is critical inangiotensin II-induced acceleration of atherosclerosis and aneurysmformation in hypercholesterolemic mice. Arterioscler ThrombVasc Biol 2004; 24: e174-8.
31. Ni W, Kitamoto S, Ishibashi M, et al. Monocyte chemoattractantprotein-1 is an essential inflammatory mediator in angiotensin IIinducedprogression of established atherosclerosis in hypercholesterolemicmice. Arterioscler Thromb Vasc Biol 2004; 24: 534-9.
32. Lopez-Candales A, Holmes DR, Liao S, et al. Decreased vascularsmooth muscle cell density in medial degeneration of human abdominalaortic aneurysms. Am J Pathol 1997; 150: 993-1007.
33. Henderson EL, Geng YJ, Sukhova GK, et al. Death of smoothmuscle cells and expression of mediators of apoptosis by T lymphocytesin human abdominal aortic aneurysms. Circulation 1999;99: 96-104.
34. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandinE2 synthesis in abdominal aortic aneurysms: implications forsmooth muscle cell viability, inflammatory processes, and the expansionof abdominal aortic aneurysms. Circulation 1999; 100: 48-54.
35. Sinha I, Sinha-Hikim AP, Hannawa KK, et al. Mitochondrialdependentapoptosis in experimental rodent abdominal aortic aneurysms.Surgery 2005; 138: 806-11.
36. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cellapoptosis in abdominal aortic aneurysms. Coron Artery Dis 1997;8: 623-31.
37. Curci JA. Digging in the "soil" of the aorta to understand thegrowth of abdominal aortic aneurysms. Vascular 2009; 17 (Suppl1): S21-9.
38. Ashton HA, Buxton MJ, Day NE, et al. The Multicentre AneurysmScreening Study (MASS) into the effect of abdominal aortic aneurysmscreening on mortality in men: a randomised controlled trial.Lancet 2002; 360: 1531-9.
39. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trialof screening for abdominal aortic aneurysm in women. Br J Surg 2002; 89: 283-5.
40. Thompson SG, Ashton HA, Gao L, Scott RA. Screening men forabdominal aortic aneurysm: 10 year mortality and cost effectivenessresults from the randomised Multicentre Aneurysm ScreeningStudy. BMJ 2009; 338: b2307.
41. Multicentre aneurysm screening study (MASS). Cost effectivenessanalysis of screening for abdominal aortic aneurysms based on fouryear results from randomised controlled trial. BMJ 2002; 325:1135.
42. Norman PE, Jamrozik K, Lawrence-Brown MM, et al. Populationbased randomised controlled trial on impact of screening on mortalityfrom abdominal aortic aneurysm. BMJ 2004; 329: 1259.
43. Bloch SH, Dayton PA, Ferrara KW. Targeted imaging using ultrasoundcontrast agents. Progess and opportunities for clinical and researchapplications. IEEE Eng Med Biol Mag 2004; 23: 18-29.
44. Wink MH, Wijkstra H, De La Rosette JJ, Grimbergen CA. Ultrasoundimaging and contrast agents: a safe alternative to MRI? Minim Invasive Ther Allied Technol 2006; 15: 93-100.
45. Roshanali F, Mandegar MH, Yousefnia MA, Mohammadi A, Baharvan dB. Abdominal aorta screening during transthoracic echocardiography.Echocardiography 2007; 24: 685-8.
46. Nyhsen CM, Elliott ST. Rapid assessment of abdominal aorticaneurysms by 3-dimensional ultrasonography. J Ultrasound Med 2007; 26: 223-6.
47. Goldberg A, Pakkiri P, Dai E, Lucas A, Fenster A. Measurementsof aneurysm morphology determined by 3-d micro-ultrasound imagingas potential quantitative biomarkers in a mouse aneurysmmodel. Ultrasound Med Biol 2007; 33: 1552-60.
48. Martin-McNulty B, Vincelette J, Vergona R, Sullivan ME, Wang YX. Non-invasive measurement of abdominal aortic aneurysms inintact mice by a high-frequency ultrasound imaging system. UltrasoundMed Biol 2005; 31: 745-9.
49. Kpodonu J, Ramaiah VG, Diethrich EB. Intravascular ultrasoundimaging as applied to the aorta: a new tool for the cardiovascularsurgeon. Ann Thorac Surg 2008; 86: 1391-8.
50. Long A, Rouet L, Bissery A, et al. Compliance of abdominal aorticaneurysms: evaluation of tissue Doppler imaging. Ultrasound MedBiol 2004; 30: 1099-108.
51. Long A, Rouet L, Vitry F, et al. Compliance of abdominal aorticaneurysms before and after stenting with tissue doppler imaging:evolution during follow-up and correlation with aneurysm diameter.Ann Vasc Surg 2009; 23: 49-59.
52. Luo J, Fujikura K, Tyrie LS, Tilson MD, Konofagou EE. Pulsewave imaging of normal and aneurysmal abdominal aortas in vivo.IEEE Trans Med Imaging 2009; 28: 477-86.
53. Clevert DA, Minaifar N, Kopp R, et al. Imaging of endoleaks afterendovascular aneurysm repair (EVAR) with contrast-enhanced ultrasound(CEUS). A pictorial comparison with CTA. Clin HemorheolMicrocirc 2009; 41: 151-68.
54. Sun Z. Diagnostic value of color duplex ultrasonography in thefollow-up of endovascular repair of abdominal aortic aneurysm. JVasc Interv Radiol 2006; 17: 759-64.
55. Catalano O, Lobianco R, Cusati B, Siani A. Contrast-enhancedsonography for diagnosis of ruptured abdominal aortic aneurysm.AJR Am J Roentgenol 2005; 184: 423-7.
56. Chaer RA, Gushchin A, Rhee R, et al. Duplex ultrasound as thesole long-term surveillance method post-endovascular aneurysmrepair: a safe alternative for stable aneurysms. J Vasc Surg 2009;49: 845-9; discussion 9-50.
57. Nyman R, Eriksson MO. The future of imaging in the managementof abdominal aortic aneurysm. Scand J Surg 2008; 97: 110-5.
58. Mortele KJ, McTavish J, Ros PR. Current techniques of computedtomography. Helical CT, multidetector CT, and 3D reconstruction.Clin Liver Dis 2002; 6: 29-52.
59. Stavropoulos SW, Charagundla SR. Imaging techniques for detectionand management of endoleaks after endovascular aortic aneurysmrepair. Radiology 2007; 243: 641-55.
60. Broeders IA, Blankensteijn JD. Preoperative imaging of the aortoiliacanatomy in endovascular aneurysm surgery. Semin VascSurg 1999; 12: 306-14.
61. Fillinger MF. Postoperative imaging after endovascular AAA repair.Semin Vasc Surg 1999; 12: 327-38.
62. Armerding MD, Rubin GD, Beaulieu CF, et al. Aortic aneurysmaldisease: assessment of stent-graft treatment-CT vs. conventionalangiography. Radiology 2000; 215: 138-46.
63. Rozenblit AM, Patlas M, Rosenbaum AT, et al. Detection ofendoleaks after endovascular repair of abdominal aortic aneurysm:value of unenhanced and delayed helical CT acquisitions. Radiology 2003; 227: 426-33.
64. Bley TA, Chase PJ, Reeder SB, et al. Endovascular abdominalaortic aneurysm repair: non-enhanced volumetric CT for follow-up.radiology 2009; 253(1): 253-62.
65. Manning BJ, Kristmundsson T, Sonesson B, Resch T. Abdominalaortic aneurysm diameter: a comparison of ultrasound measurementswith those from standard and three-dimensional computedtomography reconstruction. J Vasc Surg 2009; 50: 263-8.
66. Vidakovic R, Feringa HH, Kuiper RJ, et al. Comparison with computedtomography of two ultrasound devices for diagnosis of abdominalaortic aneurysm. Am J Cardiol 2007; 100: 1786-91.
67. Pathak AP, Gimi B, Glunde K, et al. Molecular and functionalimaging of cancer: Advances in MRI and MRS. Methods Enzymol 2004; 386: 3-60.
68. Zhang Z, Nair SA, McMurry TJ. Gadolinium meets medicinalchemistry: MRI contrast agent development. Curr Med Chem 2005; 12: 751-78.
69. Pautler RG, Fraser SE. The year(s) of the contrast agent micro-MRI in the new millennium. Curr Opin Immunol 2003; 15: 385-92.
70. de Roos A, Doornbos J, Baleriaux D, Bloem HL, Falke TH. Clinicalapplications of gadolinium-DTPA in MRI. Magn Reson Annu 1988: 113-45.
71. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagneticiron oxide nanoparticle probes for molecular imaging. Ann BiomedEng 2006; 34: 23-38.
72. Sardelic F, Fletcher JP, Ho D, Simmons K. Assessment of abdominalaortic aneurysm with magnetic resonance imaging. AustralasRadiol 1995; 39: 107-11.
73. Honda T, Hamada M, Matsumoto Y, Matsuoka H, Hiwada K. Diagnosis of thrombus and blood flow in aortic aneurysm usingtagging cine magnetic resonance imaging. Int J Angiol 1999; 8: 57-61.
74. Wicky S, Fan CM, Geller SC, et al. MR angiography of endoleakwith inconclusive concomitant CT angiography. AJR Am J Roentgenol 2003; 181: 736-8.
75. Raman VK, Karmarkar PV, Guttman MA, et al. Real-time magneticresonance-guided endovascular repair of experimental abdominalaortic aneurysm in swine. J Am Coll Cardiol 2005; 45:2069-77.
76. Schrader R. Contrast material-induced renal failure: an overview. JInterv Cardiol 2005; 18: 417-23.
77. Stacul F. Reducing the risks for contrast-induced nephropathy.Cardiovasc Interv Radiol 2005; 28 (Suppl 2): S12-8.
78. Brockow K. Contrast media hypersensitivity--scope of the problem.Toxicology 2005; 209: 189-92.
79. Idee JM, Pines E, Prigent P, Corot C. Allergy-like reactions toiodinated contrast agents. A critical analysis. Fundam Clin Pharmacol 2005; 19: 263-81.
80. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markersof abdominal aortic aneurysm presence and progression. Circulation 2008; 118: 2382-92.
81. Peremans K, Cornelissen B, Van Den Bossche B, Audenaert K, Van de Wiele C. A review of small animal imaging planar and pinholespect gamma camera imaging. Vet Radiol Ultrasound 2005;46: 162-70.
82. Ryo UY, Pinsky SM. Radionuclide angiography with 99m technetium-RBCs. CRC Crit Rev Clin Radiol Nucl Med 1976; 8: 107-28.
83. Stavropoulos SW, Itkin M, Lakhani P, et al. Detection of endoleaksafter endovascular aneurysm repair with use of technetium-99msulfur colloid and 99mTc-labeled red blood cell scans. J Vasc IntervRadiol 2006; 17: 1739-43.
84. Heyns AD, Lotter MG, Badenhorst PN, et al. Kinetics and fate ofindium 111 oxine-labeled platelets in patients with aortic aneurysms.Arch Surg 1982; 117: 1170-4.
85. Sinzinger H, O'Grady J, Fitscha P, Silberbauer K, Hofer R. Detectionof aneurysms by gamma-camera imaging after injection ofautologous labelled platelets. Lancet 1984; 2: 1365-7.
86. Forstrom L, Thorpe P, Weir EK, Johnson T. Detection of an abdominalaneurysm by indium-111 platelet imaging. Clin Nucl Med 1985; 10: 683-5.
87. Hanson SR, Kotze HF, Pieters H, Heyns AD. Analysis of indium-111 platelet kinetics and imaging in patients with aortic grafts andabdominal aortic aneurysms. Arteriosclerosis 1990; 10: 1037-44.
88. Bourekas EC, Tupler RH, Turbiner EH. Indium-111 imaging of aninflammatory abdominal aortic aneurysm. J Nucl Med 1992; 33:1553-5.
89. Mandalapu BP, Amato M, Stratmann HG. Technetium Tc 99msestamibi myocardial perfusion imaging: current role for evaluationof prognosis. Chest 1999; 115: 1684-94.
90. Van Damme H, Pierard L, Gillain D, et al. Cardiac risk assessmentbefore vascular surgery: a prospective study comparing clinicalevaluation, dobutamine stress echocardiography, and dobutamineTc-99m sestamibi tomoscintigraphy. Cardiovasc Surg 1997; 5: 54-64.
91. Iida H, Eberl S. Quantitative assessment of regional myocardialblood flow with thallium-201 and SPECT. J Nucl Cardiol 1998; 5:313-31.
92. Verani MS. Thallium-201 single-photon emission computed tomography(SPECT) in the assessment of coronary artery disease. Am JCardiol 1992; 70: 3E-9E.
93. Murata Y, Yamada I, Umehara I, Shibuya H. Tl-201 myocardialSPECT in patients with systemic arterial diseases. Clin Nucl Med 1998; 23: 832-5.
94. Chen T, Kuwabara Y, Tsutsui H, et al. The usefulness of dipyridamolethallium-201 single photon emission computed tomographyfor predicting perioperative cardiac events in patients undergoingnon-cardiac vascular surgery. Ann Nucl Med 2002; 16: 45-53.
95. Harafuji K, Chikamori T, Kawaguchi S, et al. Value of pharmacologicstress myocardial perfusion imaging for preoperative riskstratification for aortic surgery. Circ J 2005; 69: 558-63.
96. Massoud TF, Gambhir SS. Molecular imaging in living subjects:seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-80.
97. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007;48: 18N, 21N.
98. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scannerfor clinical oncology. J Nucl Med 2000; 41: 1369-79.
99. Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphyfor sentinel node mapping using a hybrid SPECT/CT system. JNucl Med 2003; 44: 1413-20.
100. Catana C, Wu Y, Judenhofer MS, et al. Simultaneous acquisition ofmultislice PET and MR images: initial results with a MRcompatiblePET scanner. J Nucl Med 2006; 47: 1968-76.
101. Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imagingin small animal research. Cell Oncol 2006; 28: 127-39.
102. Pomper MG, Lee JS. Small animal imaging in drug development.Curr Pharm Des 2005; 11: 3247-72.
103. Cheong WF, Prahl SA, Welch AJ. A review of the optical propertiesof biological tissues. IEEE J 1990; 26: 2166-85.
104. Frangioni JV. In vivo near-infrared fluorescence imaging. CurrOpin Chem Biol 2003; 7: 626-34.
105. Tedesco MM, Terashima M, Blankenberg FG, et al. Analysis of insitu and ex vivo vascular endothelial growth factor receptor expressionduring experimental aortic aneurysm progression. ArteriosclerThromb Vasc Biol 2009; 29: 1452-7.
106. Taroni P, Danesini G, Torricelli A, et al. Clinical trial of timeresolvedscanning optical mammography at 4 wavelengths between683 and 975 nm. J Biomed Opt 2004; 9: 464-73.
107. Intes X. Time-domain optical mammography SoftScan: initialresults. Acad Radiol 2005; 12: 934-47.
108. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, andfuture of annexin A5: from protein discovery to clinical applications.J Nucl Med 2005; 46: 2035-50.
109. Sarda-Mantel L, Coutard M, Rouzet F, et al. 99mTc-annexin-Vfunctional imaging of luminal thrombus activity in abdominal aorticaneurysms. Arterioscler Thromb Vasc Biol 2006; 26: 2153-9.
110. Chatziioannou AF. Instrumentation for molecular imaging in preclinicalresearch: Micro-PET and Micro-SPECT. Proc Am ThoracSoc 2005; 2: 533-6, 10-11.
111. Berman DS, Kiat H, Van Train K, et al. Dual-isotope myocardialperfusion SPECT with rest thallium-201 and stress Tc-99msestamibi. Cardiol Clin 1994; 12: 261-70.
112. Gambhir SS. Molecular imaging of cancer with positron emissiontomography. Nat Rev Cancer 2002; 2: 683-93.
113. Stickel JR, Qi J, Cherry SR. Fabrication and characterization of a0.5-mm lutetium oxyorthosilicate detector array for high-resolutionPET applications. J Nucl Med 2007; 48: 115-21.
114. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Applicationof annihilation coincidence detection to transaxial reconstructiontomography. J Nucl Med 1975; 16: 210-24.
115. Phelps ME. PET: the merging of biology and imaging into molecularimaging. J Nucl Med 2000; 41: 661-81.
116. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summaryof the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
117. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDGPET uptake--the role of PET/CT. Eur Radiol 2006; 16: 1054-65.
118. Sakalihasan N, Van Damme H, Gomez P, et al. Positron emissiontomography (PET) evaluation of abdominal aortic aneurysm(AAA). Eur J Vasc Endovasc Surg 2002; 23: 431-6.
119. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanningto the evaluation of abdominal aortic aneurysm. Semin Vasc Surg 2004; 17: 144-53.
120. Krupnick AS, Lombardi JV, Engels FH, et al. 18-fluorodeoxyglucosepositron emission tomography as a novel imaging tool forthe diagnosis of aortoenteric fistula and aortic graft infection--acase report. Vasc Endovascular Surg 2003; 37: 363-6.
121. Defawe OD, Hustinx R, Defraigne JO, Limet R, Sakalihasan N. Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominalaortic aneurysm: high accumulation in macrophages seen on PETimaging and immunohistology. Clin Nucl Med 2005; 30: 340-1.
122. Davison JM, Montilla-Soler JL, Broussard E, et al. F-18 FDG PETCTimaging of a mycotic aneurysm. Clin Nucl Med 2005; 30: 483-7.
123. Defawe OD, Thiry A, Lapiere CM, Limet R, Sakalihasan N. Primarysarcoma of an abdominal aortic aneurysm. Abdom Imaging 2006; 31: 117-9.
124. Choi SJ, Lee JS, Cheong MH, Byun SS, Hyun IY. F-18 FDGPET/CT in the management of infected abdominal aortic aneurysmdue to Salmonella. Clin Nucl Med 2008; 33: 492-5.
125. van Assen S, Houwerzijl EJ, van den Dungen JJ, Koopmans KP.Vascular graft infection due to chronic Q fever diagnosed with fusionpositron emission tomography/computed tomography. J VascSurg 2007; 46: 372.
126. Menezes LJ, Kotze CW, Hutton BF, et al. Vascular inflammationimaging with 18F-FDG PET/CT: when to image? J Nucl Med 2009;50: 854-7.
127. Reeps C, Essler M, Pelisek J, et al. Increased 18F-fluorodeoxyglucoseuptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aorticwall instability, and acute symptoms. J Vasc Surg 2008; 48: 417-23; discussion 24.
128. Truijers M, Kurvers HA, Bredie SJ, Oyen WJ, Blankensteijn JD. Invivo imaging of abdominal aortic aneurysms: increased FDG uptakesuggests inflammation in the aneurysm wall. J Endovasc Ther 2008; 15: 462-7.
129. Truijers M, Pol JA, Kurvers H, et al. Incidental finding of malignancyin patients preoperatively evaluated for aneurysm wall pathologyusing PET/CT. J Vasc Surg 2009; 49: 1313-5.
130. Wasselius J, Malmstedt J, Kalin B, et al. High 18F-FDG Uptake insynthetic aortic vascular grafts on PET/CT in symptomatic and asymptomaticpatients. J Nucl Med 2008; 49: 1601-5.
131. Kotze CW, Menezes LJ, Endozo R, et al. Increased metabolicactivity in abdominal aortic aneurysm detected by 18Ffluorodeoxyglucose(18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg 2009; 38: 93-9.
132. Choke E, Cockerill G, Wilson WR, et al. A review of biologicalfactors implicated in abdominal aortic aneurysm rupture. Eur JVasc Endovasc Surg 2005; 30: 227-44.
133. Lander ES, Linton LM, Birren B, et al. Initial sequencing andanalysis of the human genome. Nature 2001; 409: 860-921.
134. Workman P. The impact of genomic and proteomic technologies onthe development of new cancer drugs. Ann Oncol 2002; 13 (Suppl4): 115-24.
135. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomictechnologies for individualisation and improvement of cancertreatment. Eur J Cancer 2004; 40: 2623-32.
136. Choke E, Thompson MM, Jones A, et al. Gene expression profileof abdominal aortic aneurysm rupture. Ann N Y Acad Sci 2006;1085: 311-4.
137. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49 (Suppl 2): 113S-28S.
138. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers fortumor angiogenesis. Curr Pharm Des 2008; 14: 2943-73.
139. Tait JF. Imaging of apoptosis. J Nucl Med 2008; 49: 1573-6.
140. Rudd JH, Fayad ZA. Imaging atherosclerotic plaque inflammation.Nat Clin Pract Cardiovasc Med 2008; 5 (Suppl 2): S11-7.
141. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis.Arterioscler Thromb Vasc Biol 2009; 29: 1009-16.
142. Cai W, Chen X. Nanoplatforms for targeted molecular imaging inliving subjects. Small 2007; 3: 1840-54.
143. Hong H, Gao T, Cai W. Molecular imaging with single-walledcarbon nanotubes. Nano Today 2009; 4: 252-61.